Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Nykode Therapeutics ASA is an Oslo-based clinical-stage biopharmaceutical platform company founded in 2006, dedicated to discovering and developing novel vaccines and immunotherapies for cancer, autoimmune diseases, and infectious diseases. The company leverages its proprietary Vaccibody™ technology, which targets antigens to antigen-presenting cells to induce rapid, strong, and long-lasting immune responses, addressing high unmet medical needs. Key product candidates include VB10.16, a therapeutic cancer vaccine in Phase II trials for HPV16-positive cancers such as cervical cancer, and VB10.NEO, an individualized neoantigen immunotherapy in Phase 1b for advanced tumors. Nykode also advances programs like abi-suva and a tolerance platform, with collaborations alongside Roche, Regeneron, Genentech, MSD, and others enhancing its oncology and infectious disease efforts. Headquartered in Oslo Science Park with around 135 employees, Nykode Therapeutics plays a significant role in biotechnology by pioneering modular immunotherapy solutions rooted in University of Oslo research.
NOK 0.24
+NOK 0.00 (+1.24%)
EOD Jul 1, 2026
Revenue declined 100.0% YoY. The question is whether this is cyclical or a structural shift.
Negative free cash flow of -$29M. The business is consuming cash, not generating it.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$0.00
▼ -100.0% YoY
Net Income (TTM)
-$15M
▲ +62.5% YoY
Op. Margin
—
ROIC
-21.37%
▲ +0.4pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$29M
▲ +31.6% YoY
Op. Cash Flow (TTM)
-$27M
▲ +30.9% YoY
Net Debt
-$57M
Net Cash Position
Cash & Equiv.
$60M
Continue Research
Nykode Therapeutics ASA (NYKD.XOSL)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in .
On quality, Nykode Therapeutics ASA scores 10/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. It currently yields about 318.9%; see dividend safety for coverage and history. All figures are computed from SEC filings; read the full methodology. This is analysis, not investment advice.
Nykode Therapeutics ASA scores 10 out of 100 on Intrinsiqq's quality score, a weighted blend of 4 metrics each scored 0 to 100, which makes it a lower-quality business on these measures. Recent fundamentals include a -21.4% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
Yes, Nykode Therapeutics ASA pays a regular dividend of about $0.08 per share per year (typically in quarterly installments), a yield of roughly 318.9% at the current price. A low headline yield is not the same as a weak dividend: what matters is how well earnings and free cash flow cover the payout and whether it is growing, not the percentage alone. For NYKD.XOSL's full payout history, growth streak and dividend-safety score, see the dividends tab.
That depends on valuation and quality together, not either alone. you should weigh NYKD.XOSL's valuation and scores 10/100 on quality (lower-quality). It also yields about 318.9%. A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.